2014

iCo Therapeutics Announces Strategic Advisory Team Dr. Julia Levy, Dr. George Lasezkay, Richard Glickman to provide

strategic input to the Vancouver biotech firm



    VANCOUVER, Nov. 30 /PRNewswire/ - iCo Therapeutics Inc. announced today
 the company's newly-formed Strategic Advisory Team. Team members Dr. Julia
 Levy, Dr. George Lasezkay and Richard Glickman will assist iCo's management
 team and Board chart the company's strategy for growth and development.
     "We are extremely pleased to have such an esteemed group of science and
 business advisors helping us to achieve our goals," said Andrew Rae, iCo
 President and CEO.
     Dr. Julia Levy, co-founder and former President and CEO of QLT Inc., is
 currently Executive Chairman of the Scientific Advisory Board at QLT. Under
 Dr. Levy's stewardship QLT rose to become one the leading biotech companies
 worldwide with the launch of Visudyne in 2000 to treat age-related macular
 degeneration. A former microbiology professor at the University of British
 Columbia and a Fellow of the Royal Society of Canada, Dr. Levy was selected
 Female Entrepreneur of the Year for International Business in 1998 by Canadian
 Business magazine, and appointed to the Order of Canada in 2001. She received
 a B.A. (Hon.) from the University of British Columbia and a Ph.D. in
 experimental pathology from the University of London.
     Dr. Lasezkay is a principal in Turning Point Consultants, LLC, a
 consultancy group that advises life science companies on strategy and business
 development, and he is a former Corporate Vice President of Corporate
 Development at Allergan, a global ophthalmology pharmaceutical company. He
 also has extensive experience in hospital pharmacy practice, clinical
 pharmacokinetics consultation, drug research and pharmacy education.
 Dr. Lasezkay earned B.S. Pharmacy and Doctor of Pharmacy degrees from the
 State University of New York at Buffalo and a J.D. degree from the University
 of Southern California Law Center. He currently serves as a director of
 Valentis Inc., Collagenex Pharmaceuticals, Acuity Pharmaceuticals, Sucampo
 Pharmaceuticals, and Novagali Pharma, SA.
     Mr. Richard Glickman is co-founder, CEO and Chairman of Aspreva
 Pharmaceuticals Corporation and has a successful track record raising capital
 for pharmaceutical and biopharmaceutical companies, including Stressgen
 Biotechnologies Corp., where he served as CEO. Mr. Glickman was the founder
 and director of Ontario Molecular Diagnostics, a former director of the
 Canadian Genetic Diseases Network and a co-founder of Probtec Corp. where, as
 vice-president he established and introduced Canada's first licensed DNA-based
 forensic and paternity testing service. Mr. Glickman has received both
 Canada's and British Columbia's Top 40 under 40 Awards for entrepreneurs and
 was the Ernst & Young 2004 Entrepreneur of the Year recipient for Life
 Sciences.
 
     iCo Therapeutics Inc. is an emerging, Vancouver-based biotechnology
 company focused on developing pre-existing drugs for a range of new conditions
 affecting isolated biological environments - areas such as the eye, spinal
 cord, or joints - where locally-administered application of these therapies
 would have minimal systemic distribution and fewer safety issues.
 
     For more information, visit the company website at:
     www.icotherapeutics.com
 
     Business Development Contact:        Finance/Investor Contact:
     Dr. John Clement, CTO                Mr. John Meekison, CFO
     778.688.0644                         604.602.9414
 
     Media Contact:
     Elayne Wandler
     ABLE Communications
     604.831.2506
 
 

SOURCE iCo Therapeutics Inc.

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.